NO20055767L - Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr - Google Patents

Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr

Info

Publication number
NO20055767L
NO20055767L NO20055767A NO20055767A NO20055767L NO 20055767 L NO20055767 L NO 20055767L NO 20055767 A NO20055767 A NO 20055767A NO 20055767 A NO20055767 A NO 20055767A NO 20055767 L NO20055767 L NO 20055767L
Authority
NO
Norway
Prior art keywords
addiction
mammal
therapy
prevention
pharmaceutical preparation
Prior art date
Application number
NO20055767A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Steven Bradley Sands
Philip A Iredale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20055767L publication Critical patent/NO20055767L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2005-12-05 Sammendrag O. nr. E42463 Det beskrives farmasøytiske preparater for behandling av nikotinavhengighet eller -addiksjon, tobakkavhengighet eller -addiksjon, reduksjon av nikotinavvenningssymptomer eller understøttelse av opphør eller reduksjon av tobakksanvendelse eller substansmisbruk eller annen oppførselsavhengighet. De farmasøytiske preparater består av en terapeutisk effektiv kombinasjon av en nikotinisk reseptorpartialagonist og en CB-1 reseptorantagonist og en farmasøytisk akseptabel bærer. Det beskrives metoder for å anvende disse forbindelser.
NO20055767A 2003-05-09 2005-12-05 Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr NO20055767L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46942903P 2003-05-09 2003-05-09
PCT/IB2004/001552 WO2004098580A2 (en) 2003-05-09 2004-05-05 A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Publications (1)

Publication Number Publication Date
NO20055767L true NO20055767L (no) 2005-12-05

Family

ID=33435233

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055767A NO20055767L (no) 2003-05-09 2005-12-05 Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr

Country Status (13)

Country Link
US (1) US20040224963A1 (no)
EP (1) EP1624895A2 (no)
JP (1) JP2006525992A (no)
KR (1) KR20060009314A (no)
CN (1) CN1784243A (no)
AU (1) AU2004237153A1 (no)
BR (1) BRPI0410173A (no)
CA (1) CA2525225A1 (no)
CO (1) CO5700713A2 (no)
MX (1) MXPA05012088A (no)
NO (1) NO20055767L (no)
RU (1) RU2005131497A (no)
WO (1) WO2004098580A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
EA003669B1 (ru) * 1998-04-29 2003-08-28 Пфайзер Продактс Инк. Конденсированные с арилом азаполициклические соединения
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity

Also Published As

Publication number Publication date
AU2004237153A1 (en) 2004-11-18
WO2004098580A3 (en) 2005-01-06
CN1784243A (zh) 2006-06-07
WO2004098580A2 (en) 2004-11-18
RU2005131497A (ru) 2006-06-27
CA2525225A1 (en) 2004-11-18
KR20060009314A (ko) 2006-01-31
EP1624895A2 (en) 2006-02-15
US20040224963A1 (en) 2004-11-11
CO5700713A2 (es) 2006-11-30
JP2006525992A (ja) 2006-11-16
MXPA05012088A (es) 2006-02-22
BRPI0410173A (pt) 2006-05-16

Similar Documents

Publication Publication Date Title
Simons et al. Clinical pharmacology of new histamine H1 receptor antagonists
Das et al. A survey of the structures of US FDA approved combination drugs
Ströberg et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference
WO2008045817A3 (en) Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage
ES2171356A1 (es) Uso de combinaciones que comprenden antihistaminas no sedantes y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe.
WO2006044643A3 (en) Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
Weigmann et al. Distribution of clozapine and desmethylclozapine between blood and brain in rats
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
WO2005107726A3 (en) Method for the treatment of back pain
GB9902689D0 (en) Organic compounds
MY130803A (en) New quinuclidine amide derivatives
WO2002094273A3 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
WO2007088489A3 (en) Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
Campbell et al. Antinociceptive effects of alcohol and nicotine: involvement of the opioid system
WO2004000840A3 (en) Quinuclidine derivatives and pharmaceutical compositions containing the same
WO2006058007A3 (en) Jnk inhibitors for treatment of cns injury
EP1078637A3 (en) Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug
Desager et al. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
CY1110152T1 (el) Χρηση συνδυασμου μορφινης και τουλαχιστον ενος ανταγωνιστη φυσικου οπιοειδους στην αγωγη της εξαρτησης απο φυσικα οπιοειδη και στην προληψη της μη στοματικης καταχρησης φυσικων οπιοειδων σε εξαρτημενους απο φυσικα οπιοειδη
NO20055767L (no) Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr
EP1186318A3 (en) Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
WO2005076829A3 (en) Stable loratadine spill resistant formulation
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application